Scynexis Gets FDA Orphan Drug Status for Triterpenoid antifungal

FDA designated Scynexis’s drug as orphan treatment for invasive candidiasis.

• FDA awarded designation to the treatment, which has generic name Triterpenoid Antifungal, on March 15.
• Orphan drugs are entitled to 7 yrs mkt exclusivity if approved by FDA for rare disease

FDA notice: Link

To contact Bloomberg News for this story:
+1-212-617-2000 or newsauto@bloomberg.net

© 2026 Bloomberg L.P. All rights reserved. Used with permission.